Effect of hyperbaric oxygen therapy on chronic neurocognitive deficits of post-traumatic brain injury patients: retrospective analysis

HBOT – What does it do, and how does it treat medical conditions :

The latest seminar by the best experts on healing the brain from Israel, June 2019


Prof Shai Efrati is the leader in the field of treatment utilising HBOT and achieving what DRUGS can’t.

Israeli Researchers Assaf Harofe find Hyperbaric Oxygen therapy was associated with significant cognitive improvements.

And if we are talking about previous studies with 1.2 ATA on 21% inhaled oxygen (ie, air) cannot be regarded as an inert or sham control!!!!

« In addition to objective evaluations, there are inherent ethical and logistic difficulties in handling the sham control in HBOT trials. HBOT includes two active ingredients: pressure and oxygen. Pressure is needed to increase plasma oxygen, but the pressure change alone may also have significant cellular effects. Additionally, the greatest effect of pressure is in human tissues that are under tight autoregulation pressure control, such as the brain, where the intracranial pressure is normally 0.0092–0.0197 atm.23 24 To generate a pressure sensation, the chamber pressure must be 1.2 ATA or higher. However, such a change in environmental pressure (from 1 ATA to 1.2 ATA) and subsequent tissue oxygenation (with an increase of tissue oxygenation by at least 50%) has a significant biological effect. Thus, sham therapy in previous studies using 1.2 ATA on 21% inhaled oxygen (ie, air) cannot be regarded as an inert or sham control but rather as a lower dose of the active ingredient.4 20 In regards to a possible effect of vasoconstriction of the large blood vessels induced by hyperbaric oxygen—it has been well established that the tissues are saturated by hyperoxia and do not suffer from hypoxia, as the vasoconstriction effect is compensated by increased plasma oxygen content and microvascular blood flow.

Any increase in pressure, even with reduced oxygen percentage, cannot serve as a true placebo, but rather as a low dosage of the active ingredient, further supporting the need for objective data gathered from large cohorts of patients suffering from PCS and treated by HBOT.

Source: https://bmjopen.bmj.com/content/8/9/e023387

Laisser un commentaire